The Bamberg-based, medium-sized enterprise is further expanding its product range with the two products VEREGEN® and TAMSUBLOCK® DUO.
Bamberg 12 May 2020
Following the conclusion of an exclusive sales agreement with Aresus Pharma GmbH, Dr. Pfleger Arzneimittel GmbH is to take over the marketing of VEREGEN® 10% ointment.
“VEREGEN® 10% ointment complements our existing product portfolio in an optimal way and we are convinced of its potential in dermatology, urology and gynaecology,” say Dr. Günter Auerbach and Ralf Will, Managing Directors of Dr. Pfleger Arzneimittel GmbH.
“We are very pleased that with Dr. Pfleger we have been able to win a strong partner for the marketing of VEREGEN® 10% ointment in Germany. We will continue to further the scientific and clinical development together with Dr. Pfleger,” add Sven Schimansky-Wabra and Dr. Francisco Harrison, Managing Directors of Aresus Pharma GmbH.
In addition, Dr Pfleger Arzneimittel GmbH will be launching the combination preparation TAMSUBLOCK® DUO (dutasteride 0.5 mg / tamsulosin 0.4 mg)
Already since 2006, Dr. Pfleger’s monopreparation TAMSUBLOCK® has been one of the most frequently prescribed tamsulosins in urology. Dr. Pfleger’s product range also includes the 5-alpha reductase inhibitor Finural®.
Company profile Dr. Pfleger Arzneimittel
Dr. Pfleger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 390 employees and a turnover of almost €100 million in 2019.
Among the company’s best-known non-prescription products are the pain reliever Neuralgin®, the ipalat® throat pastille, the antimycotic Mykosert® and the extensive Bio-H-Tin® product line for hair and nails.
The company is owned by the foundation Doktor Robert Pfleger-Stiftung, to which the company’s surpluses flow.